Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-O-acetylated-GD2 monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- OGD2 Pharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-O-acetylated-GD2 monoclonal antibody is an investigational immunotherapy designed to target O-acetylated-GD2 (OAcGD2) ganglioside, an antigen found in high concentrations on the surface of various cancer cells, including neuroblastoma, glioblastoma, and breast cancer stem cells. Unlike the non-acetylated GD2, OAcGD2 is not significantly expressed on normal peripheral nerve fibers, which aims to mitigate the severe neuropathic pain commonly associated with anti-GD2 therapies. The antibody exerts its anti-tumor effects through multiple mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of tumor cell apoptosis via pathways involving caspase-3. Developed by OGD2 Pharma, this drug has received orphan drug designation for neuroblastoma and is currently in preclinical development for several oncology indications.
- Other names
- anti-OAcGD2 mAbanti-OAcGD-2 mAbanti-OAcGD 2 mAbchimeric monoclonal antibody to O-acetyl-GD2 antigen
02
Targets
OAcGD2 (O-acetyl-GD2)
Beyond the preview
Go deeper on Anti-O-acetylated-GD2 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-O-acetylated-GD2 monoclonal antibody.